

Ganirelix Formulation

Vers 5.1	sion	Revision Date: 2023/09/26		S Number: 07-00021	Date of last issue: 2023/03/20 Date of first issue: 2014/10/15			
1. PI	1. PRODUCT AND COMPANY IDENTIFICATION							
	Product	name	:	Ganirelix Formula	ation			
		cturer or supplier's d	letai					
	Compa	ny	:	Organon & Co.				
	Addres	5	:	JL Raya Pandaar Pandaan, Jawa T				
	Telepho	one	:	+1-551-430-6000	1			
	Emerge	ency telephone number	· :	+1-215-631-6999				
	E-mail a	address	:	EHSSTEWARD@	0organon.com			
	Recom	mended use of the cl	nemi	cal and restrictio	ns on use			
		mended use ions on use	:	Pharmaceutical Not applicable				

2. HAZARDS IDENTIFICATION

GHS Classification Reproductive toxicity	:	Category 1B
Specific target organ toxicity - repeated exposure	:	Category 1 (Bone marrow, Liver, Adrenal gland, spleen, Ovary)
GHS label elements Hazard pictograms	:	
Signal word	:	Danger
Hazard statements	:	H360Fd May damage fertility. Suspected of damaging the un- born child. H372 Causes damage to organs (Bone marrow, Liver, Adrenal gland, spleen, Ovary) through prolonged or repeated exposure.
Precautionary statements	:	Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe mist or vapours.



Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/03/20
5.1	2023/09/26	22207-00021	Date of first issue: 2014/10/15

P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Ganirelix	124904-93-4	>= 0.01 -< 0.3

4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	May damage fertility. Suspected of damaging the unborn child. Causes damage to organs through prolonged or repeated exposure.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection,





Version 5.1	Revision Date: 2023/09/26		DS Number: 207-00021	Date of last issue: 2023/03/20 Date of first issue: 2014/10/15
Notes to physician		:	and use the recommended personal protective equipmen when the potential for exposure exists (see section 8). Treat symptomatically and supportively.	
5. FIREFI	GHTING MEASURES			
Suitable extinguishing media		:	Water spray Alcohol-resistant Carbon dioxide (C Dry chemical	
Unsu medi	uitable extinguishing ia	:	None known.	
Spec fighti	cific hazards during fire-	:	Exposure to com	pustion products may be a hazard to health.
•	ardous combustion prod-	:	No hazardous co	mbustion products are known
Spec ods	cific extinguishing meth-	:	cumstances and to Use water spray to	measures that are appropriate to local cir- the surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do
	cial protective equipment refighters	:	In the event of fire	e, wear self-contained breathing apparatus. tective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
Environmental precautions	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	Soak up with inert absorbent material. For large spills, provide dyking or other appropriate contain- ment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor- bent. Local or national regulations may apply to releases and dis- posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter- mine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.



Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/03/20
5.1	2023/09/26	22207-00021	Date of first issue: 2014/10/15

7. HANDLING AND STORAGE

Technical measures		See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.	
Local/Total ventilation		If sufficient ventilation is unavailable, use with local exhaust ventilation.	
Advice on safe handling		Do not get on skin or clothing. Do not breathe mist or vapours. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as- sessment Keep container tightly closed. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the	
Conditions for safe storage		environment. Keep in properly labelled containers.	
		Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.	
Materials to avoid	:	Do not store with the following product types: Strong oxidizing agents	

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Ganirelix	124904-93-4	TŴA	0.2 μg/m3 (OEB 5)	Internal
		Wipe limit	2 µg/100 cm ²	Internal

Engineering measures:Use closed processing systems or containment technologies
to control at source (e.g., glove boxes/isolators) and to pre-
vent leakage of compounds into the workplace.
All engineering controls should be implemented by facility
design and operated in accordance with GMP principles to
protect products, workers, and the environment.
No open handling permitted.
Totally enclosed processes and materials transport systems
are required.
Operations require the use of appropriate containment tech-
nology designed to prevent leakage of compounds into the
workplace.Personal protective equipment

Respiratory protection : No personal respiratory protective equipment normally re-

Ganirelix Formulation



Version 5.1	Revision Date: 2023/09/26	SDS Number: 22207-00021	Date of last issue: 2023/03/20 Date of first issue: 2014/10/15
Hand	protection	quired.	
Ма	iterial	: Chemical-resist	ant gloves
	marks rotection	If the work envi mists or aeroso Wear a faceshi	e gloving. asses with side shields or goggles. ronment or activity involves dusty conditions, ils, wear the appropriate goggles. eld or other full face protection if there is a ect contact to the face with dusts, mists, or
Skin a	nd body protection	Additional body task being perfe posable suits) t	r laboratory coat. garments should be used based upon the prmed (e.g., sleevelets, apron, gauntlets, dis- o avoid exposed skin surfaces. e degowning techniques to remove potentially lathing
Hygie	ne measures	: If exposure to c eye flushing sys ing place. When using do Wash contamin The effective of engineering con appropriate deg	hemical is likely during typical use, provide stems and safety showers close to the work- not eat, drink or smoke. hated clothing before re-use. beration of a facility should include review of htrols, proper personal protective equipment, gowning and decontamination procedures, ne monitoring, medical surveillance and the

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	Aqueous solution
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
рН	:	5
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	100 °C
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available



Ganirelix Formulation

/ersion 5.1	Revision Date: 2023/09/26		S Number: 207-00021	Date of last issue: 2023/03/20 Date of first issue: 2014/10/15
	r explosion limit / Upper ability limit	:	No data available	9
	explosion limit / Lower ability limit	:	No data available	9
Vapou	ur pressure	:	23 hPa (20 °C)	
Relati	ve vapour density	:	No data available	9
Relati	ve density	:	1	
	ility(ies) ater solubility	:	completely misci	ble
	on coefficient: n- ol/water	:	No data available	9
	gnition temperature	:	No data available	9
Decor	mposition temperature	:	No data available	9
Viscos Vis	sity scosity, kinematic	:	No data available	2
Explo	sive properties	:	Not explosive	
Oxidiz	ring properties	:	The substance o	r mixture is not classified as oxidizing.
Molec	ular weight	:	No data available	9
Partic	le size	:	No data available	9

10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac-	:	Can react with strong oxidizing agents.
tions		
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of	:	Inhalation
exposure		Skin contact
		Ingestion
		Eye contact



Ganirelix Formulation

Version	Revision Date:	SDS N
5.1	2023/09/26	22207-

Number:)7-00021

Date of last issue: 2023/03/20 Date of first issue: 2014/10/15

Acute toxicity

Not classified based on available information.

Components:

Ganirelix:

Acute toxicity (other routes of : LD50 (Rat): 40 mg/kg administration)

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Ganirelix:

Species	:	Rabbit
Result	:	Mild eye irritation
Method	:	Draize Test

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Ganirelix:

Test Type	:	Maximisation Test
Species	:	Guinea pig
Result	:	negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Ganirelix: Genotoxicity in vitro

Test Type: reverse mutation assay Test system: Salmonella typhimurium Result: negative

Test Type: reverse mutation assay Test system: Escherichia coli Result: negative

Test Type: in vitro assay Test system: Chinese hamster ovary cells





Result: negative Genotoxicity in vivo : Test Type: In vivo micronucleus test Species: Mouse Application Route: Intravenous Result: negative Gern cell mutagenicity - Assessment : Weight of evidence does not support classification as a gern cell mutagen. Carcinogenicity Mot classified based on available information. : Reproductive toxicity May damage fertility. Suspected of damaging the unborn child. Components: : Sanirelix: Effects on fertility : Test Type: Fertility/early embryonic development Species: Rat Application Route: Subcutaneous Duration of Single Treatment: 13 Weeks Fertility: LOAEL: 0.1 µg/kg Result: Effects on fertility Test Type: Fertility/early embryonic development Species: Rat, female Application Route: Subcutaneous Duration of Single Treatment: 13 Weeks Fertility: LOAEL: 0.1 µg/kg Result: Iffects on fertility Test Type: Fertility: Coale: 10 µg/kg Result: No effects on mating performance, Effects on fertility Species: Rat, female Application Route: Subcutaneous Errity: DOAEL: 0.0 µg/kg body weight Result: Fiftects on fertility Effects on foetal develop: ment : Test Type: Embryo-foetal development Species: Rat, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 10 µg/kg Result: Effects on fertility Effects on foetal develop: ment : Test Type: Embryo-foetal development Species: Rat, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 10 µg/kg Result: Effects on fertility Species: Rat, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 10 µg/kg Result: Effects on fertility <th>Version 5.1</th> <th>Revision Date: 2023/09/26</th> <th></th> <th>Number: 07-00021</th> <th>Date of last issue: 2023/03/20 Date of first issue: 2014/10/15</th>	Version 5.1	Revision Date: 2023/09/26		Number: 07-00021	Date of last issue: 2023/03/20 Date of first issue: 2014/10/15
Genotoxicity in vivo : Test Type: In vivo micronucleus test Species: Mouse Application Route: Intravenous Result: negative Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen. Carcinogenicity May damage fertility. : Weight of evidence does not support classification as a germ cell mutagen. Carcinogenicity May damage fertility. : Weight of evidence does not support classification as a germ cell mutagen. Carcinogenicity May damage fertility. : Weight of evidence does not support classification as a germ cell mutagen. Carcinogenicity May damage fertility. : Support classified based on available information. Reproductive toxicity May damage fertility. : Support classified based on available information. Reproductive toxicity May damage fertility. : Support classified based on available information. Components: : Components: : Support classified based on available information. Species: Rat Application Route: Subcutaneous Duration of Single Treatment: 13 Weeks Fertility: LOAEL: 0.1 µg/kg Result: Effects on fertility Species: Rat, female Application Route: Subcutaneous Fertility: NOAEL: 10 µg/kg Result: Effects on fertility Effects on foetal develop- ment : Test Type: Fertility Species: Rat, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 30 µg/kg Result: Embryo-foetal toxicity: LOAEL: 30 µg/kg Result: Embryo-foetal toxicity: LOAEL: 30 µg/kg					
Species: Mouse Application Route: Intravenous Result: negative Germ cell mutagenicity - Assessment cell mutagen. Carcinogenicity Not classified based on available information. Reproductive toxicity May damage fertility. Suspected of damaging the unborn child. Components: Ganirelix: Effects on fertility : Test Type: Fertility/early embryonic development Species: Rat Application Route: Subcutaneous Duration of Single Treatment: 13 Weeks Fertility: LOAEL: 0.1 µg/kg Result: Effects on fertility Species: Rat, female Application Route: Subcutaneous Duration of Single Treatment: 8 Weeks Fertility: LOAEL: 0.1 µg/kg Result: No effects on mating performance, Effects on fertility Species: Rat, female Application Route: Subcutaneous Duration of Single Treatment: 8 Weeks Fertility: LOAEL: 0.1 µg/kg Result: Effects on fertility Species: Rat, female Application Route: Subcutaneous Erst Type: Entryo-foetal development Species: Rat, female Application Route: Subcutaneous Entryo-foetal toxicity: LOAEL: 10 µg/kg Result: Effects on fertility Test Type: Embryo-foetal development Species: Rat, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 10 µg/kg Result: Embryo-foetal toxicity: CoAEL: 10 µg/kg Result: Embryo-foetal toxicity: LOAEL: 30 µg/kg			F	Result: negative	
Assessment cell mutagen. Carcinogenicity Not classified based on available information. Reproductive toxicity May damage fertility. Suspected of damaging the unborn child. Components: Ganirelix: Effects on fertility Effects on fertility Test Type: Fertility/early embryonic development Species: Rat Application Route: Subcutaneous Duration of Single Treatment: 13 Weeks Fertility: LOAEL: 0.1 µg/kg Result: Effects on fertility Test Type: Fertility/early embryonic development Species: Rat, female Application Route: Subcutaneous Duration of Single Treatment: 8 Weeks Fertility: LOAEL: 10 µg/kg Result: No effects on mating performance, Effects on fertility Species: Monkey Application Route: Subcutaneous Fertility: NOAEL: 0.02 mg/kg body weight Result: Effects on foetal development Species: Rat, female Application Route: Subcutaneous Fertility: NOAEL: 0.02 mg/kg body weight Result: Effects on fertility Effects on foetal development ment Test Type: Embryo-foetal development Species: Rat, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 10 µg/kg Result: Embryo-foetal development Species: Rat, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 10 µg/kg Result: Embryo-foetal development Species: Rabbit, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 30 µg/kg Result: Embryo-foetal toxicity	Geno	otoxicity in vivo	S A	Species: Mouse	
Not classified based on available information. Reproductive toxicity May damage fertility. Suspected of damaging the unborn child. Components: Ganirelix: Effects on fertility : Test Type: Fertility/early embryonic development Species: Rat Application Route: Subcutaneous Duration of Single Treatment: 13 Weeks Fertility: LOAEL: 0.1 µg/kg Result: Effects on fertility Test Type: Fertility/early embryonic development Species: Rat, female Application Route: Subcutaneous Duration of Single Treatment: 8 Weeks Fertility: LOAEL: 10 µg/kg Result: No effects on mating performance, Effects on fertility Species: Monkey Application Route: Subcutaneous Duration Route: Subcutaneous Buration of Route: Subcutaneous Fertility: NOAEL: 10 µg/kg Result: Effects on fertility Species: Rat, female Application Route: Subcutaneous Fertility: NOAEL: 0.02 mg/kg body weight Result: Effects on fertility : Test Type: Embryo-foetal development Species: Rat, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 10 µg/kg Result: Embryo-foetal development Species: Rat, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 10 µg/kg Result: Embryo-foetal development Species: Rabit, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 30 µg/kg Result: Embryo-foetal development Species: Rabit, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 30 µg/kg Result: Embryo-foetal doxicity: LOAEL: 30 µg/kg				-	ce does not support classification as a germ
May damage fertility. Suspected of damaging the unborn child. Components: Ganirelix: Effects on fertility : Test Type: Fertility/early embryonic development Species: Rat Application Route: Subcutaneous Duration of Single Treatment: 13 Weeks Fertility: LOAEL: 0.1 µg/kg Result: Effects on fertility Test Type: Fertility/early embryonic development Species: Rat, female Application Route: Subcutaneous Duration of Single Treatment: 8 Weeks Fertility: LOAEL: 10 µg/kg Result: No effects on mating performance, Effects on fertility Test Type: Fertility/Species: Monkey Application Route: Subcutaneous Fertility: NOAEL: 0.02 mg/kg body weight Result: Effects on fertility Effects on foetal develop- ment : Test Type: Embryo-foetal development Species: Rat, female Application Route: Subcutaneous Emtily: NOAEL: 0.02 mg/kg body weight Result: Effects on fertility Effects on foetal develop- ment : Test Type: Embryo-foetal development Species: Rat, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 10 µg/kg Result: Embryo-foetal development Species: Rat, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 30 µg/kg Result: Embryo-foetal toxicity			able in	formation.	
Ganirelix: Effects on fertility : Test Type: Fertility/early embryonic development Species: Rat Application Route: Subcutaneous Duration of Single Treatment: 13 Weeks Fertility: LOAEL: 0.1 µg/kg Result: Effects on fertility Test Type: Fertility/early embryonic development Species: Rat, female Application Route: Subcutaneous Duration of Single Treatment: 8 Weeks Fertility: LOAEL: 10 µg/kg Result: No effects on mating performance, Effects on fertility Test Type: Fertility Species: Monkey Application Route: Subcutaneous Fertility: NOAEL: 0.02 mg/kg body weight Result: Effects on fertility Effects on foetal develop- ment : Test Type: Embryo-foetal development Species: Rat, female Application Route: Subcutaneous Fertility: NOAEL: 0.02 mg/kg body weight Result: Effects on fertility Effects on foetal develop- ment : Test Type: Embryo-foetal development Species: Rat, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 10 µg/kg Result: Embryo-foetal toxicity Test Type: Embryo-foetal development Species: Rabit, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 30 µg/kg Result: Embryo-foetal toxicity: LOAEL: 30 µg/kg	-		cted of	damaging the ur	nborn child.
Effects on fertility: Test Type: Fertility/early embryonic development Species: Rat Application Route: Subcutaneous Duration of Single Treatment: 13 Weeks Fertility: LOAEL: 0.1 µg/kg Result: Effects on fertilityTest Type: Fertility/early embryonic development Species: Rat, female Application Route: Subcutaneous Duration of Single Treatment: 8 Weeks Fertility: LOAEL: 10 µg/kg Result: No effects on mating performance, Effects on fertilityTest Type: Fertility Species: Monkey Application Route: Subcutaneous Fertility: NOAEL: 0.02 mg/kg body weight Result: Effects on fertilityEffects on foetal develop- ment: Test Type: Embryo-foetal development Species: Rat, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 10 µg/kg Result: Embryo-foetal toxicityEffects on foetal develop- ment: Test Type: Embryo-foetal development Species: Rat, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 10 µg/kg Result: Embryo-foetal toxicityEffects on foetal develop- ment: Test Type: Embryo-foetal development Species: Rat, female Application Route: Subcutaneous Embryo-foetal toxicityEffects is type: Embryo-foetal toxicity: Test Type: Embryo-foetal development Species: Rabbit, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 10 µg/kg Result: Embryo-foetal toxicity: LOAEL: 30 µg/kg Result: Embryo-foetal toxicity	<u>Com</u>	ponents:			
 Species: Rat Application Route: Subcutaneous Duration of Single Treatment: 13 Weeks Fertility: LOAEL: 0.1 µg/kg Result: Effects on fertility Test Type: Fertility/early embryonic development Species: Rat, female Application Route: Subcutaneous Duration of Single Treatment: 8 Weeks Fertility: LOAEL: 10 µg/kg Result: No effects on mating performance, Effects on fertility Test Type: Fertility Species: Monkey Application Route: Subcutaneous Fertility: NOAEL: 0.02 mg/kg body weight Result: Effects on fertility Test Type: Embryo-foetal development Species: Rat, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 10 µg/kg Result: Embryo-foetal toxicity Test Type: Embryo-foetal development Species: Rat, female Application Route: Subcutaneous Embryo-foetal toxicity Test Type: Embryo-foetal development Species: Rat, female Application Route: Subcutaneous Embryo-foetal toxicity Test Type: Embryo-foetal development Species: Rabbit, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 30 µg/kg Result: Embryo-foetal toxicity 	Gani	relix:			
 Species: Rat, female Application Route: Subcutaneous Duration of Single Treatment: 8 Weeks Fertility: LOAEL: 10 µg/kg Result: No effects on mating performance, Effects on fertility Test Type: Fertility Species: Monkey Application Route: Subcutaneous Fertility: NOAEL: 0.02 mg/kg body weight Result: Effects on fertility Effects on foetal develop- ment Test Type: Embryo-foetal development Species: Rat, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 10 µg/kg Result: Embryo-foetal development Species: Rabbit, female Application Route: Subcutaneous Embryo-foetal toxicity Test Type: Embryo-foetal development Species: Rabbit, female Application Route: Subcutaneous Embryo-foetal toxicity 	Effec	ts on fertility	S <i>A</i> [F	Species: Rat Application Route Duration of Single Fertility: LOAEL:	e: Subcutaneous e Treatment: 13 Weeks 0.1 µg/kg
 Species: Monkey Application Route: Subcutaneous Fertility: NOAEL: 0.02 mg/kg body weight Result: Effects on fertility Effects on foetal development Species: Rat, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 10 µg/kg Result: Embryo-foetal development Species: Rabbit, female Application Route: Subcutaneous Embryo-foetal toxicity 			S / [F	Species: Rat, fem Application Route Duration of Single Fertility: LOAEL:	nale e: Subcutaneous e Treatment: 8 Weeks 10 μg/kg
mentSpecies: Rat, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 10 μg/kg Result: Embryo-foetal toxicityTest Type: Embryo-foetal development Species: Rabbit, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 30 μg/kg Result: Embryo-foetal toxicity			s A F	Species: Monkey Application Route Fertility: NOAEL:	e: Subcutaneous 0.02 mg/kg body weight
Species: Rabbit, female Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 30 µg/kg Result: Embryo-foetal toxicity			S A E	Species: Rat, fen Application Route Embryo-foetal to	nale e: Subcutaneous kicity: LOAEL: 10 μg/kg
Reproductive toxicity - As- : Clear evidence of adverse effects on sexual function and fer			S A E	Species: Rabbit, Application Route Embryo-foetal to	female e: Subcutaneous κicity: LOAEL: 30 μg/kg
	Repr	oductive toxicity - As-	: (Clear evidence o	f adverse effects on sexual function and fer





	Version 5.1	Revision Date: 2023/09/26	SDS Number: 22207-00021	Date of last issue: 2023/03/20 Date of first issue: 2014/10/15	
--	----------------	------------------------------	----------------------------	---	--

sessment

ity, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs (Bone marrow, Liver, Adrenal gland, spleen, Ovary) through prolonged or repeated exposure.

Components:

Ganirelix:

Exposure routes	:	Ingestion
Target Organs	:	Bone marrow, Liver, Adrenal gland, spleen, Ovary
Assessment	:	Causes damage to organs through prolonged or repeated
		exposure.

Repeated dose toxicity

Components:

Ganirelix:

Species NOAEL LOAEL Application Route Exposure time Target Organs	 Rat 0.02 mg/kg 2 mg/kg Subcutaneous 6 Months Bone marrow
Species LOAEL Application Route Exposure time Target Organs	 Mouse, female 0.3 mg/kg Subcutaneous 3 Months Liver, Adrenal gland, spleen, Ovary
Species LOAEL Application Route Exposure time Target Organs	Mouse, male 3 mg/kg Subcutaneous 3 Months Liver, Adrenal gland, spleen
Species NOAEL Application Route Exposure time Remarks	Monkey 2.5 mg/kg Subcutaneous 6 Months No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.



Ganirelix Formulation

Version 5.1	Revision Date: 2023/09/26	-	DS Number: 2207-00021	Date of last issue: 2023/03/20 Date of first issue: 2014/10/15
Exp	erience with human ex	pos	ure	
<u>Con</u>	nponents:			
Gan	irelix:			
Inha	lation	:		most common side effects are:, vaginal iche, Abdominal pain, Nausea, ectopic preg- ge
12. ECO	OGICAL INFORMATIC	N		
Eco	toxicity			
<u>Con</u>	nponents:			
Gan	irelix:			
	toxicology Assessmen	t		
Acut	e aquatic toxicity	:	No data availabl	e
Chro	onic aquatic toxicity	:	No data availabl	e
	sistence and degradab	ility		
	accumulative potential lata available			
	ility in soil lata available			
	er adverse effects lata available			
13. DISP	OSAL CONSIDERATIO	NS		
Disp	oosal methods			
-	te from residues	:		of waste into sewer.
Con	taminated packaging	:	Empty container dling site for rec	cordance with local regulations. is should be taken to an approved waste han- ycling or disposal. specified: Dispose of as unused product.
14. TRAN	SPORT INFORMATIO	N		
Inte	rnational Regulations			
UN ı Prop Clas	RTDG number ber shipping name s sidiary risk	:	Not applicable Not applicable Not applicable Not applicable	



Ganirelix Formulation

Version 5.1	Revision Date: 2023/09/26		DS Number: 207-00021	Date of last issue: 2023/03/20 Date of first issue: 2014/10/15
Packi	ng group		Not applicable	
Label		÷	Not applicable	
ΙΑΤΑ-	DGR			
			Not applicable	
	er shipping name	:	Not applicable	
Class		÷	Not applicable	
	diary risk	÷	Not applicable	
	ng group	÷	Not applicable	
Label		:	Not applicable	
Packi	ng instruction (cargo	:	Not applicable	
aircra	•			
	ng instruction (passen- rcraft)	:	Not applicable	
•	-Code			
	umber		Not applicable	
	er shipping name	:	Not applicable	
Class		:	Not applicable	
	diary risk	:	Not applicable	
	ng group	:	Not applicable	
Label		:	Not applicable	
EmS	-	÷	Not applicable	
	e pollutant	:	Not applicable	
Trans	sport in bulk according	j to	Annex II of MARF	POL 73/78 and the IBC Code
Not a	pplicable for product as	sup	plied.	
Speci	ial precautions for use	r		
Not a	pplicable			
15. REGU	LATORY INFORMATIC	N		
Safet ture	y, health and environn	nent	tal regulations/leg	gislation specific for the substance or mix
ter of		lo. 8	87/M-IND/PER/9/2	R/4/2013 concerning the Revision of Min 009 concerning Globally Harmonized Sys 5.
Regu	lation of the Minister o	of He	ealth No. 472 of 1	996 on the Safeguarding of Substances

Hazardous to Health

Hazardous substances that must be registered : Not applicable

Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances

Hazardous substances approved for use	:	Not applicable
Prohibited substances	:	Not applicable
Restricted substances	:	Not applicable



Ganirelix Formulation

Version 5.1	Revision Date: 2023/09/26	SDS Number: 22207-00021	Date of last issue: 2023/03/20 Date of first issue: 2014/10/15	

Regulation of the Ministry of Trade No. 7 of 2022 on Distribution and Control of Hazardous Materials

Type of hazardous materials subject to distribution and : Not applicable control, Annex I

Type of hazardous materials subject to distribution and : Not applicable control, Annex II

The components of this product are reported in the following inventories:

AICS		not determined
DSL	:	not determined
IECSC	:	not determined

16. OTHER INFORMATION

Revision Date	:	2023/09/26
Further information		
Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/
Date format	:	yyyy/mm/dd

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumu-



Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/03/20
5.1	2023/09/26	22207-00021	Date of first issue: 2014/10/15

lative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ID / EN